Emerging Insights on Adverse Events During ART and Implications for Treatment: Nephrotoxicity and Long-Acting Injectables

In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity and the use of NRTI-sparing regimens with discussion of the GEMINI-1 and -2 studies of DTG/3TC and the SWORD-1 and -2 studies of DTG/RPV, and safety with long-acting injectables with specific discussion of the ATLAS and FLAIR studies of LA CAB plus RPV and the CUSTOMIZE study.Presenters:Fidelia Bernice, PharmDClinical Pharmacy SpecialistInfectious DiseasesDepartment of PharmacyUniversity of Maryland Medical CenterBaltimore, MarylandAadia I. Rana, MDAssociate Professor of MedicineDivision of Infectious DiseasesUniversity of Alabama at Birmingham1917 ClinicBirmingham, AlabamaContent based on a CME program supported by independent educational grants fromJanssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.Link to full program:https://bit.ly/3ydMtcL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.